These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

487 related items for PubMed ID: 17292123

  • 1. An antisense oligonucleotide carrier based on amino silica nanoparticles for antisense inhibition of cancer cells.
    Peng J, He X, Wang K, Tan W, Li H, Xing X, Wang Y.
    Nanomedicine; 2006 Jun; 2(2):113-20. PubMed ID: 17292123
    [Abstract] [Full Text] [Related]

  • 2. Poly(L-lysine)-modified silica nanoparticles for the delivery of antisense oligonucleotides.
    Zhu SG, Xiang JJ, Li XL, Shen SR, Lu HB, Zhou J, Xiong W, Zhang BC, Nie XM, Zhou M, Tang K, Li GY.
    Biotechnol Appl Biochem; 2004 Apr; 39(Pt 2):179-87. PubMed ID: 15032738
    [Abstract] [Full Text] [Related]

  • 3. One-pot synthesis of sustained-released doxorubicin silica nanoparticles for aptamer targeted delivery to tumor cells.
    He X, Hai L, Su J, Wang K, Wu X.
    Nanoscale; 2011 Jul; 3(7):2936-42. PubMed ID: 21623439
    [Abstract] [Full Text] [Related]

  • 4. Nanoparticle formulation enhances the delivery and activity of a vascular endothelial growth factor antisense oligonucleotide in human retinal pigment epithelial cells.
    Aukunuru JV, Ayalasomayajula SP, Kompella UB.
    J Pharm Pharmacol; 2003 Sep; 55(9):1199-206. PubMed ID: 14604462
    [Abstract] [Full Text] [Related]

  • 5. VP22 light controlled delivery of oligonucleotides to ocular cells in vitro and in vivo.
    Normand N, Valamanesh F, Savoldelli M, Mascarelli F, BenEzra D, Courtois Y, Behar-Cohen F.
    Mol Vis; 2005 Mar 04; 11():184-91. PubMed ID: 15761390
    [Abstract] [Full Text] [Related]

  • 6. Simplified preparation via streptavidin of antisense oligomers/carriers nanoparticles showing improved cellular delivery in culture.
    Wang Y, Nakamura K, Liu X, Kitamura N, Kubo A, Hnatowich DJ.
    Bioconjug Chem; 2007 Mar 04; 18(4):1338-43. PubMed ID: 17605463
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of malarial topoisomerase II in Plasmodium falciparum by antisense nanoparticles.
    Föger F, Noonpakdee W, Loretz B, Joojuntr S, Salvenmoser W, Thaler M, Bernkop-Schnürch A.
    Int J Pharm; 2006 Aug 17; 319(1-2):139-46. PubMed ID: 16713146
    [Abstract] [Full Text] [Related]

  • 8. Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells.
    Li SD, Huang L.
    Mol Pharm; 2006 Aug 17; 3(5):579-88. PubMed ID: 17009857
    [Abstract] [Full Text] [Related]

  • 9. Delivery of antisense oligonucleotides to leukemia cells by RNA bacteriophage capsids.
    Wu M, Sherwin T, Brown WL, Stockley PG.
    Nanomedicine; 2005 Mar 17; 1(1):67-76. PubMed ID: 17292060
    [Abstract] [Full Text] [Related]

  • 10. A calcium phosphate nanoparticle-based biocarrier for efficient cellular delivery of antisense oligodeoxynucleotides.
    Hou S, Ma H, Ji Y, Hou W, Jia N.
    ACS Appl Mater Interfaces; 2013 Feb 17; 5(3):1131-6. PubMed ID: 23323641
    [Abstract] [Full Text] [Related]

  • 11. Comparison of antisense oligonucleotide drug delivery systems.
    Weyermann J, Lochmann D, Zimmer A.
    J Control Release; 2004 Dec 10; 100(3):411-23. PubMed ID: 15567506
    [Abstract] [Full Text] [Related]

  • 12. Biocompatible silica nanoparticles-insulin conjugates for mesenchymal stem cell adipogenic differentiation.
    Liu D, He X, Wang K, He C, Shi H, Jian L.
    Bioconjug Chem; 2010 Sep 15; 21(9):1673-84. PubMed ID: 20735012
    [Abstract] [Full Text] [Related]

  • 13. Efficient delivery of intact phosphodiester oligonucleotides by poly-beta-amino esters.
    Remaut K, Symens N, Lucas B, Demeester J, De Smedt SC.
    J Control Release; 2010 May 21; 144(1):65-74. PubMed ID: 20114066
    [Abstract] [Full Text] [Related]

  • 14. In vivo study of biodistribution and urinary excretion of surface-modified silica nanoparticles.
    He X, Nie H, Wang K, Tan W, Wu X, Zhang P.
    Anal Chem; 2008 Dec 15; 80(24):9597-603. PubMed ID: 19007246
    [Abstract] [Full Text] [Related]

  • 15. A novel anionic dendrimer for improved cellular delivery of antisense oligonucleotides.
    Hussain M, Shchepinov M, Sohail M, Benter IF, Hollins AJ, Southern EM, Akhtar S.
    J Control Release; 2004 Sep 14; 99(1):139-55. PubMed ID: 15342187
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Optimal effects of liposome on antisense oligodeoxynucleotides uptake by mouse breast cancer TM40D cells and the effects of antisense oligodeoxynucleotides targeting c-erbB-2 on cell proliferation and apoptosis].
    Liu XA, Fan P, Wu ZY.
    Zhonghua Wai Ke Za Zhi; 2004 Jul 07; 42(13):802-5. PubMed ID: 15363300
    [Abstract] [Full Text] [Related]

  • 18. Effects of liposomal antisense oligonucleotides on mRNA and protein levels of the HPV 16 E7 oncogene.
    Lappalainen K, Pirilä L, Jääskeläinen I, Syrjänen K, Syrjänen S.
    Anticancer Res; 1996 Jul 07; 16(5A):2485-92. PubMed ID: 8917339
    [Abstract] [Full Text] [Related]

  • 19. Enhanced antisense inhibition of human immunodeficiency virus type 1 in cell cultures by DLS delivery system.
    Lavigne C, Thierry AR.
    Biochem Biophys Res Commun; 1997 Aug 28; 237(3):566-71. PubMed ID: 9299405
    [Abstract] [Full Text] [Related]

  • 20. Albumin-protamine-oligonucleotide-nanoparticles as a new antisense delivery system. Part 2: cellular uptake and effect.
    Weyermann J, Lochmann D, Georgens C, Zimmer A.
    Eur J Pharm Biopharm; 2005 Apr 28; 59(3):431-8. PubMed ID: 15760723
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.